Muhammad Ashraf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muhammad Ashraf has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
Muhammad Saleem
Institute of Chemistry, Baghdad-ul-Jadeed Campus, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan
9 shared publicationsAmbar Iqbal
8 shared publicationsAziz- Ur- Rehman
8 shared publicationsBushra Bashir
Institute of Chemistry, Baghdad-ul-Jadeed Campus, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan
8 shared publicationsKeshab Bhattarai
Department of Pharmaceutical Biology, University of Tuebingen, Tuebingen, Germany
7 shared publications- Naheed Riaz
Institute of Chemistry, Baghdad-ul-Jadeed Campus, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan
7 shared publications
Latest Publications
- Open Access
- 10 May 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 46, 102621
Dysregulated serum levels of human tissue kallikreins, hK7 and hK10, as potential biomarkers of asthma
- 10 May 2026
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 46, 102621
Open AccessDysregulated serum levels of human tissue kallikreins, hK7 and hK10, as potential biomarkers of asthma
- 22 February 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 173, 109667
Structure-guided discovery of 4-phenyl-5-p-tolyloxymethyl-4H-1,2,4-triazole thioethers as 15-lipoxygenase inhibitors using integrated in vitro, structure-activity relationship, in silico, cytotoxicity towards MCF-7 cell line, DNA docking and MD simulation methods
- 22 February 2026
- Published by Elsevier in Bioorganic Chemistry
- Vol. 173, 109667
Structure-guided discovery of 4-phenyl-5-p-tolyloxymethyl-4H-1,2,4-triazole thioethers as 15-lipoxygenase inhibitors using integrated in vitro, structure-activity relationship, in silico, cytotoxicity towards MCF-7 cell line, DNA docking and MD simulation methods
- 11 December 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (47)
Exploring Antiurease Activity of Antibiotics: Insights From In Vitro, SAR, In Silico, DNA Docking, and MD Simulation Studies
In our continued efforts in search for antibiotics active against Helicobacter pylori (HP), the present work demonstrates the antiurease potential of aminoglycosides, tetracyclines, rifaximin, and chloramphenicol. The most active antibiotics during in vitro assays included tobramycin (IC 50 12.64 ± 0.93 µM), rifaximin (IC 50 19.47 ± 0.83 µM), oxytetracycline (IC 50 37.76 ± 0.75 µM), chloramphenicol (IC 50 58.62 ± 0.84 µM) and kanamycin (IC 50 63.75 ± 0.72 µM). Molecular docking studies revealed that rifaximin exhibited the maximum binding affinity (−8.4 kcal/mol), followed by oxytetracycline and tobramycin. The amino acid residues Asp165 and Asp223 in rifaximin, His221 and His332 in oxytetracycline, and Asn168, Gly279, Asp223, and Cyc321 in kanamycin formed conventional hydrogen bonds, and the complexes were further stabilized by hydrophobic interactions. DNA docking studies revealed minor groove binding with maximum binding free energy −10.6 kcal/mol against rifaximin and major groove binding against oxytetracycline with free energy −9.0 kcal/mol. MD simulations for 100 ns yielded RMSD values of 0.302, 0.228, and 0.275 nm for the kanamycin, oxytetracycline, and rifaximin‐receptor complexes, respectively. Analyses revealed that the strength and specificity of hydrogen bonds significantly contributed to the overall stability of the complexes. The Rg, SASA, and MMPBSA calculations revealed conformational stability and supported the in vitro findings. These studies suggest exploring new antibiotics as potential antiurease agents.
- 11 December 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (47)
Exploring Antiurease Activity of Antibiotics: Insights From In Vitro, SAR, In Silico, DNA Docking, and MD Simulation Studies
In our continued efforts in search for antibiotics active against Helicobacter pylori (HP), the present work demonstrates the antiurease potential of aminoglycosides, tetracyclines, rifaximin, and chloramphenicol. The most active antibiotics during in vitro assays included tobramycin (IC 50 12.64 ± 0.93 µM), rifaximin (IC 50 19.47 ± 0.83 µM), oxytetracycline (IC 50 37.76 ± 0.75 µM), chloramphenicol (IC 50 58.62 ± 0.84 µM) and kanamycin (IC 50 63.75 ± 0.72 µM). Molecular docking studies revealed that rifaximin exhibited the maximum binding affinity (−8.4 kcal/mol), followed by oxytetracycline and tobramycin. The amino acid residues Asp165 and Asp223 in rifaximin, His221 and His332 in oxytetracycline, and Asn168, Gly279, Asp223, and Cyc321 in kanamycin formed conventional hydrogen bonds, and the complexes were further stabilized by hydrophobic interactions. DNA docking studies revealed minor groove binding with maximum binding free energy −10.6 kcal/mol against rifaximin and major groove binding against oxytetracycline with free energy −9.0 kcal/mol. MD simulations for 100 ns yielded RMSD values of 0.302, 0.228, and 0.275 nm for the kanamycin, oxytetracycline, and rifaximin‐receptor complexes, respectively. Analyses revealed that the strength and specificity of hydrogen bonds significantly contributed to the overall stability of the complexes. The Rg, SASA, and MMPBSA calculations revealed conformational stability and supported the in vitro findings. These studies suggest exploring new antibiotics as potential antiurease agents.
- Open Access
- 7 October 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (41) , 48586-48602
Computational Evaluation of Azinane–Amide-Coupled Triazoles Enabled by an Alkali Metal Reagent as Anti-Enzymatic Agents
A new electrophile was synthesized and merged with 1,2,4-triazole and piperidine to avail the aimed library of compounds, 10a i‑v and 10b i‑v . Various 4-(substituted)benzenesulfonyl chlorides (1 i‑v ) were treated with ethyl piperidin-4-carboxylate (2a) and ethyl piperidin-3-carboxylate (2b) to acquire 3a i‑v and 3b i‑v esters bearing a sulfamoyl moiety. These esters were converted to different 1,2,4-triazoles 6a i‑v and 6b i‑v through the formation of carbohydrazides and thiosemicarbazides as intermediates. A new electrophile, compound 9, was synthesized by reaction of bromoacetyl bromide (7) with an aromatic amine (8) under basic conditions. This electrophile was treated with 6a i‑v and 6b i‑v to avail the aimed library of compounds, 10a i‑v and 10b i‑v . The structural confirmation of all of the synthesized compounds was performed through 1D NMR data. The whole library of synthesized compounds was evaluated for their pharmacological potential against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), alpha glucosidase, and urease enzymes. Compound 10a iii showed better % inhibition (63.37 ± 1.25) against the AChE enzyme, while 10b i showed better % inhibition (72.38 ± 1.21) against the BChE enzyme as compared to the reference standards, Eserine and Pyridostigmine. 10b v showed best activity against the alpha-glucosidase enzyme with 64.7 ± 1.84% inhibition and the best activity against the urease enzyme was presented by compound 10b iii with the present inhibition potential of 49.3 ± 1.5. The best biofilm inhibition activity was shown by compound 10b ii with a % inhibition of 84.03141361 against bacterium, Escherichia coli. Molecular docking was performed to check the active sites of enzymes giving different values of binding affinity. The physicochemical properties and bioactivity values of synthesized compounds rendered them as active drugs. DFT was performed to study the electronic characteristics including molecular electrostatic potential (MEP), structural optimization, and HOMO–LUMO energy gap to evaluate reactivity or stability of the synthesized compounds. Furthermore, full insight evaluation may lead us to find the best antienzymatic drug candidates in the future.
- 7 October 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (41) , 48586-48602
Open AccessComputational Evaluation of Azinane–Amide-Coupled Triazoles Enabled by an Alkali Metal Reagent as Anti-Enzymatic Agents
A new electrophile was synthesized and merged with 1,2,4-triazole and piperidine to avail the aimed library of compounds, 10a i‑v and 10b i‑v . Various 4-(substituted)benzenesulfonyl chlorides (1 i‑v ) were treated with ethyl piperidin-4-carboxylate (2a) and ethyl piperidin-3-carboxylate (2b) to acquire 3a i‑v and 3b i‑v esters bearing a sulfamoyl moiety. These esters were converted to different 1,2,4-triazoles 6a i‑v and 6b i‑v through the formation of carbohydrazides and thiosemicarbazides as intermediates. A new electrophile, compound 9, was synthesized by reaction of bromoacetyl bromide (7) with an aromatic amine (8) under basic conditions. This electrophile was treated with 6a i‑v and 6b i‑v to avail the aimed library of compounds, 10a i‑v and 10b i‑v . The structural confirmation of all of the synthesized compounds was performed through 1D NMR data. The whole library of synthesized compounds was evaluated for their pharmacological potential against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), alpha glucosidase, and urease enzymes. Compound 10a iii showed better % inhibition (63.37 ± 1.25) against the AChE enzyme, while 10b i showed better % inhibition (72.38 ± 1.21) against the BChE enzyme as compared to the reference standards, Eserine and Pyridostigmine. 10b v showed best activity against the alpha-glucosidase enzyme with 64.7 ± 1.84% inhibition and the best activity against the urease enzyme was presented by compound 10b iii with the present inhibition potential of 49.3 ± 1.5. The best biofilm inhibition activity was shown by compound 10b ii with a % inhibition of 84.03141361 against bacterium, Escherichia coli. Molecular docking was performed to check the active sites of enzymes giving different values of binding affinity. The physicochemical properties and bioactivity values of synthesized compounds rendered them as active drugs. DFT was performed to study the electronic characteristics including molecular electrostatic potential (MEP), structural optimization, and HOMO–LUMO energy gap to evaluate reactivity or stability of the synthesized compounds. Furthermore, full insight evaluation may lead us to find the best antienzymatic drug candidates in the future.
- Open Access
- 14 March 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (12) , 14005-14016
Antiurease Activity of Antibiotics: In Vitro, In Silico, Structure Activity Relationship, and MD Simulations of Cephalosporins and Fluoroquinolones
Helicobacter pylori infection is widespread in 50% of the world's population and is associated with gastric ulcers and related disorders that ultimately culminate in gastric cancer. Levofloxacin-based, or clarithromycin-based, triple therapy is frequently used to inhibit the bacterial urease enzyme for the eradication of H. pylori. A comprehensive investigation based on the urease inhibitory profiles of antibiotics and their computational implications is lacking in the scientific literature. The present study was aimed specifically to determine the antiurease activities within the realms of cephalosporins and fluoroquinolones by in vitro methods supported with in silico investigations. The results demonstrate the jack bean urease inhibitory activity of cephalosporins, wherein cefadroxil, cefpodoxime, cefotaxime, and cefaclor displayed inhibitions (IC50 21.35 ± 0.64 to 62.86 ± 0.78 μM) compared with the standard thiourea (IC50 21.25 ± 0.15 μM). Among fluoroquinolones, levofloxacin, ofloxacin, and gemifloxacin (IC50 7.24 ± 0.29 to 16.53 ± 0.85 μM) unveiled remarkable inhibitory profiles. Levofloxacin and ofloxacin exhibited competitive inhibition against the said enzyme. Ciprofloxacin and moxifloxacin displayed weak urease inhibitions. During molecular docking studies, Asp362, Gly279, Arg338, Asn168, Asp223, Gln364, and Met366 were involved in hydrogen bonding in fluoroquinolones, and hydrogen bonding was established with Arg338, His248, Asn168 residues, and metal Ni601 and Ni602 of the enzyme. MD simulations and MMPBSA results demonstrated the existence of significant protein-ligand binding. Overall, these results warrant further investigations into the significance of these active molecules in relation to their inhibitory potential against the targeted urease enzyme.
- 14 March 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (12) , 14005-14016
Open AccessAntiurease Activity of Antibiotics: In Vitro, In Silico, Structure Activity Relationship, and MD Simulations of Cephalosporins and Fluoroquinolones
Helicobacter pylori infection is widespread in 50% of the world's population and is associated with gastric ulcers and related disorders that ultimately culminate in gastric cancer. Levofloxacin-based, or clarithromycin-based, triple therapy is frequently used to inhibit the bacterial urease enzyme for the eradication of H. pylori. A comprehensive investigation based on the urease inhibitory profiles of antibiotics and their computational implications is lacking in the scientific literature. The present study was aimed specifically to determine the antiurease activities within the realms of cephalosporins and fluoroquinolones by in vitro methods supported with in silico investigations. The results demonstrate the jack bean urease inhibitory activity of cephalosporins, wherein cefadroxil, cefpodoxime, cefotaxime, and cefaclor displayed inhibitions (IC50 21.35 ± 0.64 to 62.86 ± 0.78 μM) compared with the standard thiourea (IC50 21.25 ± 0.15 μM). Among fluoroquinolones, levofloxacin, ofloxacin, and gemifloxacin (IC50 7.24 ± 0.29 to 16.53 ± 0.85 μM) unveiled remarkable inhibitory profiles. Levofloxacin and ofloxacin exhibited competitive inhibition against the said enzyme. Ciprofloxacin and moxifloxacin displayed weak urease inhibitions. During molecular docking studies, Asp362, Gly279, Arg338, Asn168, Asp223, Gln364, and Met366 were involved in hydrogen bonding in fluoroquinolones, and hydrogen bonding was established with Arg338, His248, Asn168 residues, and metal Ni601 and Ni602 of the enzyme. MD simulations and MMPBSA results demonstrated the existence of significant protein-ligand binding. Overall, these results warrant further investigations into the significance of these active molecules in relation to their inhibitory potential against the targeted urease enzyme.
- 22 March 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (24) , 15549-15568
Investigations of p -tolyloxy-1,3,4-oxadiazole propionamides as soybean 15-lipoxygenase inhibitors in comforting with in vitro and in silico studies
Inflammatory disorders are the prime contributor to public health issue and the development of more effective and safer anti-inflammatory drugs in addition to other therapeutic alternatives to treat inflammatory illnesses, particularly chronic inflammatory diseases, is one of the foremost current issues. In this regard, our present work is concerned with the synthesis of a new series of N-alkyl/aralkyl/aryl derivatives (7a–o) of 5-((p-tolyloxymethyl)-4H-1,3,4-oxadiazole-2-ylthio)propionamide which was instigated by the successive conversions of p-tolyloxyacetic acid into ester, hydrazide and 5-(p-tolyloxymethyl)-4H-1,3,4-oxadiazole-2-thiol. The planned compounds (7a–o) were attained by the reaction of 5-(p-tolyloxymethyl)-4H-1,3,4-oxadiazole-2-thiol with variety of N-alkyl/aralkyl/aryl electrophiles in potassium hydroxide and were characterized by FTIR, 1H-, 13C-NMR spectroscopy, EI-MS and HR-EI-MS spectrometry and probed for their inhibiting potential against soybean 15-lipoxygenase (15-LOX) enzyme. The compounds 7a, 7n, 7 g, 7e, 7h, 7i, 7j and 7b promulgated the potent inhibiting potential with IC50 values 9.43 ± 0.45, 16.75 ± 0.49, 19.45 ± 0.37, 21.32 ± 0.46, 22.64 ± 0.56, 23.53 ± 0.62, 24.32 ± 0.45 and 29.15 ± 0.57 µM, respectively, while excellent to good inhibitory activities were shown by 7o, 7 m, 7k, 7f, 7c, 7 l and 7d with IC50 values in the range 30.29 ± 0.56 to 52.54 ± 0.64 µM. Compounds 7i–o maintained 91.12 ± 1.5 to 98.23 ± 1.2% blood mononuclear cells (MNCs) viability at 0.25 mM by MTT assay whilst compounds 7d–h observed 46.51 ± 1.3 to 57.12 ± 1.4% viability where as the most toxic compounds were 7b (12.51 ± 1.4%), 7a (28.12 ± 1.5%) and 7c (38.23 ± 1.5%) as compared with controls. Pharmacokinetic profiles predicted good oral bioavailability and drug-likeness properties of molecules as per rule of five. Molecular docking studies displayed hydrogen bonding between the compounds and the enzyme with Arg378 which was common in 7n, 7 g, 7h and baicalein. In 7a and quercetin, hydrogen bonding was established through Asn375; Tyr512 and Val589 were also involved in bonding with other analogues. RMSD (root mean square deviation) values exhibited good inhibitory profiles in the order quercetin (0.73 Å)50 values of compounds and HOMO–LUMO (highest occupied and lowest unoccupied molecular orbitals) energy calculations. It was found that compounds with more stabilized LUMO orbitals had significant biological activity. The work collectively supports steps taken forward in search for potential ‘leads’ as anti-inflammatory agents wherein compounds 7a, 7n, 7i, 7j possessed ‘lead’ like properties for further investigations. Communicated by Ramaswamy H. Sarma
- 22 March 2023
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 41 (24) , 15549-15568
Investigations of p -tolyloxy-1,3,4-oxadiazole propionamides as soybean 15-lipoxygenase inhibitors in comforting with in vitro and in silico studies
Inflammatory disorders are the prime contributor to public health issue and the development of more effective and safer anti-inflammatory drugs in addition to other therapeutic alternatives to treat inflammatory illnesses, particularly chronic inflammatory diseases, is one of the foremost current issues. In this regard, our present work is concerned with the synthesis of a new series of N-alkyl/aralkyl/aryl derivatives (7a–o) of 5-((p-tolyloxymethyl)-4H-1,3,4-oxadiazole-2-ylthio)propionamide which was instigated by the successive conversions of p-tolyloxyacetic acid into ester, hydrazide and 5-(p-tolyloxymethyl)-4H-1,3,4-oxadiazole-2-thiol. The planned compounds (7a–o) were attained by the reaction of 5-(p-tolyloxymethyl)-4H-1,3,4-oxadiazole-2-thiol with variety of N-alkyl/aralkyl/aryl electrophiles in potassium hydroxide and were characterized by FTIR, 1H-, 13C-NMR spectroscopy, EI-MS and HR-EI-MS spectrometry and probed for their inhibiting potential against soybean 15-lipoxygenase (15-LOX) enzyme. The compounds 7a, 7n, 7 g, 7e, 7h, 7i, 7j and 7b promulgated the potent inhibiting potential with IC50 values 9.43 ± 0.45, 16.75 ± 0.49, 19.45 ± 0.37, 21.32 ± 0.46, 22.64 ± 0.56, 23.53 ± 0.62, 24.32 ± 0.45 and 29.15 ± 0.57 µM, respectively, while excellent to good inhibitory activities were shown by 7o, 7 m, 7k, 7f, 7c, 7 l and 7d with IC50 values in the range 30.29 ± 0.56 to 52.54 ± 0.64 µM. Compounds 7i–o maintained 91.12 ± 1.5 to 98.23 ± 1.2% blood mononuclear cells (MNCs) viability at 0.25 mM by MTT assay whilst compounds 7d–h observed 46.51 ± 1.3 to 57.12 ± 1.4% viability where as the most toxic compounds were 7b (12.51 ± 1.4%), 7a (28.12 ± 1.5%) and 7c (38.23 ± 1.5%) as compared with controls. Pharmacokinetic profiles predicted good oral bioavailability and drug-likeness properties of molecules as per rule of five. Molecular docking studies displayed hydrogen bonding between the compounds and the enzyme with Arg378 which was common in 7n, 7 g, 7h and baicalein. In 7a and quercetin, hydrogen bonding was established through Asn375; Tyr512 and Val589 were also involved in bonding with other analogues. RMSD (root mean square deviation) values exhibited good inhibitory profiles in the order quercetin (0.73 Å)50 values of compounds and HOMO–LUMO (highest occupied and lowest unoccupied molecular orbitals) energy calculations. It was found that compounds with more stabilized LUMO orbitals had significant biological activity. The work collectively supports steps taken forward in search for potential ‘leads’ as anti-inflammatory agents wherein compounds 7a, 7n, 7i, 7j possessed ‘lead’ like properties for further investigations. Communicated by Ramaswamy H. Sarma
- 4 January 2023
- Published by Springer Nature in Journal of the Iranian Chemical Society
- Vol. 20 (4) , 977-994
Vetting of new N-furfurylated p-chlorophenyl-1,2,4-triazole acetamides as lipoxygenase inhibitors assisted with in vitro and in silico studies
- 4 January 2023
- Published by Springer Nature in Journal of the Iranian Chemical Society
- Vol. 20 (4) , 977-994
Vetting of new N-furfurylated p-chlorophenyl-1,2,4-triazole acetamides as lipoxygenase inhibitors assisted with in vitro and in silico studies